GlassScriptPhysician profile
Thanh Cao
NPI 1073963583
$4,105.23
in general payments reported to CMS, 2019-2025
27 companies · $766 in 2025
The $766 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2021: $509 · 2022: $1,160 · 2023: $553 · 2024: $831 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Education: $83.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.39 |
| Education | $83.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $621.74 | 2019-2022 | |
| Gilead Sciences, INC. | $602.67 | 2022-2025 | Biktarvy |
| Janssen Biotech, INC. | $463.42 | 2022-2024 | Tecvayli, Darzalex, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $329.57 | 2021-2025 | |
| Inari Medical, INC. | $235.73 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $234.16 | 2022-2024 | Farxiga, Calquence |
| Amgen INC. | $147.37 | 2021-2024 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $133.88 | 2021-2025 | Acthar |
| Fresenius Kabi USA, LLC | $124.78 | 2024 | Smoflipid |
| Aurinia Pharma U.S., INC. | $123.86 | 2024 | Lupkynis |
| Medtronic, INC. | $122.78 | 2025 | Symplicity G3 |
| Akebia Therapeutics INC | $121.36 | 2021 | |
| Ardelyx, INC. | $119.72 | 2024 | Xphozah 30 Mg |
| Boston Scientific Corporation | $118.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.75 | 2022-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $110.93 | 2019 | |
| Nxstage Medical, INC. | $108.28 | 2022-2024 | |
| Vifor Pharma, INC. | $50.87 | 2021-2022 | |
| Pfizer INC. | $36.92 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $35.70 | 2022 | |
| Lilly USA, LLC | $34.16 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $23.45 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.61 | 2021 | |
| Dexcom, INC. | $19.25 | 2025 | Dexcom G6 Transmitter |
| Opko Pharmaceuticals, LLC | $18.49 | 2021 | |
| Fresenius USA Marketing, INC. | $16.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thanh Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.